Parham Habibzadeh: How the COMPETE Trial Could Reshape Treatment Sequencing for Progressive GEP-NETs
7h agoen
From the article
Parham Habibzadeh, Internal Medicine Resident at UPMC, shared a post on X: “Phase 3 COMPETE trial just published in the Lancet [¹⁷⁷Lu] Lu-edotreotide significantly outperforms everolimus in advanced, progressive somatostatin […]
Continue reading on OncoDailyYou might also wanna read
Real-World EV Plus Pembro Success Seen in Urothelial Cancer
Medscape·21h ago
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
doi.org·6d ago
GE HealthCare and Mayo Clinic launch theranostics study to personalize prostate cancer treatment
GE HealthCare and Mayo Clinic have launched the MI-BET research collaboration, a theranostics study aimed at developing a more personalized
mayocl.in·16h ago
Triple hormone drug retatrutide shows promise for diabetes and weight loss in Lancet trial
A new triple hormone drug called retatrutide, which mimics GLP-1, GIP, and glucagon, has shown promising results in a Lancet-published trial
theguardian.com·1mo agoPhase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus
clinicaltrials.gov·8d ago
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
clinicaltrials.gov·7d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.